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3 
Abstract 
  
An improved understanding of gene signaling pathways and mechanisms involved in 
cancer continues to be a necessary feat to further cancer research and yield effective cancer 
treatments. Many cancers involve the misregulation of transcription factors E2f, c-Myc, FoxM1, 
and Stat family members, which are responsible for regulating many genes in the cell. While 
some gene targets of these transcription factors are known, many more are yet to be discovered. 
Identification of all the direct gene targets will provide not only the unidentified pathways, but 
also a better idea of the interconnectedness of the misregulated pathways in cancer. 
The project employs an information retrieval and integration approach to identify all the 
potential direct targets of E2fs, c-Myc, FoxM1, and Stat in order to understand the relationship 
between these regulators as well as their respective roles in cancer.  As the medical community 
delves further into researching cancer treatments, there is an increasing demand for an effective 
and reliable tool that assimilates massive amounts of existing information regarding relevant 
cancer pathways and provides easy access through a single portal. This project aims to mine data 
from existing public repositories and ongoing experiments to process and calibrate it to a certain 
standard, so that searching for details about transcription factors and potential targets will be 
easier.  
The data is categorized in multiple ways to make queries and searches more efficient. 
Every data entry has information regarding the source of the experiments, type of target gene 
regulation, experimental variables, and confidence score. The confidence score assigned to each 
essentially classifies the gene as a high or low stringency target gene. Currently, manual retrieval 
of data has yielded entries corresponding to about 3000 target genes amassed from over 600 
publications concerning E2fs, Myc, Stat, and FoxM1. We have also computationally extracted 
4 
data from relevant supplementary microarray raw data files. Furthermore, we aim to improve the 
precision of the confidence score given to each target gene by utilizing the influx of all new 
relevant data. The collective data obtained will serve to provide researchers with comprehensive 
information on gene-signaling pathways in various cancers with the goal of improving current 
research, instigating new ideas, and identifying potential targets of cancer treatments. 
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Introduction 
 
Cancer encompasses a number of diseases that result from the abnormal and uncontrolled 
proliferation of cells. The basic mechanism by which cancer arises involves genetic mutations 
that eventually lead to misregulated signaling pathways. A “direct transcriptional target” of a 
transcription factor is a gene whose regulatory DNA sequences are physically bound by the 
transcription factor. Transcription factors themselves are DNA-specific binding proteins that 
control the rate of gene expression. They can act as activators or repressors leading to the 
upregulation or downregulation of genes, respectively. Within a cell, transcription factors engage 
in complex formation with other molecules including co-activators, co-repressors, co-factors, 
and histones that together bind to target genes and engage the transcriptional machinery. E2Fs, c-
Myc, Stat, and FoxM1 are examples of such transcription factors.  
E2f and c-Myc  
 
Many cancers are known to have mutations in tumor suppressor genes and transcription 
factors. One such tumor suppressor gene is retinoblastoma (RB) which encodes a nuclear protein 
(Rb) that exhibits cell cycle control in the G1 and G2 phases
1
. Deletion or inactivation of both 
RB alleles plays an essential, rate-limiting role in retinoblastoma and osteosarcomas that arise 
within families that carry a mutated RB gene. Previous studies in mouse models have shown that 
Rb has dual roles in gating cell cycle progression and promoting cellular differentiation
2
.  
E2F is a large transcription family consisting of three activators: E2F1, E2F2, E2F3a, and 
six repressors: E2F3b, E2F4-8. In the biological system, Rb sequesters E2F to regulate entry of 
cell cycle. The role of Rb as an indirect regulator of E2F target gene expression has also been 
demonstrated in previous studies
3
. Numerous cancer types involve the misregulation of the 
Rb/E2F pathway, underlining the importance of identifying the entire cadre of E2F target genes 
6 
and in gaining a comprehensive understanding of the pathway
3
. 
 
Figure i: E2f family members.
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Rb also regulates the activities of other classes of the transcription factors involved in 
processes of cell proliferation and differentiation
4
. Thus, Rb is significant not only as a tumor 
suppressor but also as a mediator in gene communication
4
. Another potential transcription factor 
target of Rb is c-Myc, which regulates about 15 percent of human genes in cancer cells, 
including those involved in cell division, cell growth, and apoptosis
5
. c-Myc, a specific member 
within the 3-member Myc transcription family, is found to be constitutively expressed and 
activated in many cancers, leading to the misregulation of many genes in the human body
6
. 
However, whether Myc activity is impacted with an Rb mutation is unknown.  
While both E2F and Myc transcription factors are misregulated in cancer, if and how 
these transcription factors communicate and collaborate in cancer initiation and progression 
7 
remains to be determined. Therefore, the relationship between the E2F and the c-Myc signaling 
pathways needs further analysis. Moreover, the identification of direct transcriptional targets of 
E2F and Myc will serve to further understand the relationship between these two pathways in the 
context of cancers with Rb mutations. 
FoxM1 
 
 FoxM1 is a unique transcription factor known to be involved in cell proliferation and cell 
cycle progression
7
. It is a member of the forkhead box family of helix-turn helix proteins and in 
humans consists of three members including FoxM1a, b, and c. Endogenous FoxM1 is 
upregulated at the S and G2/M phases in the cell. Accordingly, FoxM1 regulates the expression 
of many G2/M genes, such as mitotic cyclins, that are essential for proper mitotic cell division 
and chromosome stability
8
.  Therefore it is unsurprising that FoxM1 null-embryos result in 
embryonic lethality due to high polyploidy in cells of the heart and liver
9
.  
FoxM1 is frequently upregulated in many human cancers. Though it is known to play a 
key role in tumor initiation, growth, and progression, the mechanism by which FoxM1 initiates 
tumorigenesis is still unknown
7
. FoxM1 is also regulated by proliferative and anti-proliferative 
signals and proto-oncogenes and tumor suppressors, specifically p53
10
. Since these factors are 
often mutated in cancers, FoxM1 expression is directly affected, thus leading to the 
misregulation of a large number of genes.  
8 
 
Figure ii: FoxM1 targeted pathways.
16
 
   Studies have shown that c-Myc, E2f1, and E2f3 are FoxM1 targets
11
. Therefore, 
elucidating the pathways involving FoxM1 and other transcription factors can provide 
researchers with a better understanding of tumorigenesis.  
Stat  
Another transcription factor that is known to be misregulated in cancer is Stat. Signal 
transducer and activation of transcription (Stat) consists of a family of latent cytoplasmic 
transcription factors including Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b, and Stat6. They are 
downstream effectors of cytokine and growth factor receptor signaling. Constitutively activated 
Stat proteins have been detected in many cancers and primary tumors
12
. More specifically, 
constitutively activated Stat3 is known to play key role in oncogenesis and tumor angiogenesis 
13
. In cancers, uncontrolled signaling of both Stat3 and Stat5 has been demonstrated to contribute 
9 
to cell proliferation and prevent apoptosis.  
 
Figure iii: Regulation of JAK-STAT signaling in the immune system.
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While Stat3 has already been utilized as a potential target of cancer treatments 
14
, there is 
still a need to elucidate downstream pathways regulated by all Stat proteins, including Stat3. This 
is necessary in order to understand the role of Stat proteins in oncogenesis and tumor initiation. 
Moreover, the relationship between Stat gene signaling pathways and those of other transcription 
factors such as E2fs, and c-Myc, and FoxM1 is still unknown and necessitates investigation.  
The database: what, why, and how 
 
Database web sites for identifying target genes already exist but the criteria used to define 
them are unclear and often unknown to the user. Also, most of these sites are not openly 
available to the scientific community and are quickly outdated. As a result, the information 
10 
offered by these sites is limited and unconvincing to most researchers. The proposed project 
presents a clear and precise way to classify and understand ‘gene targets’ by taking advantage of 
the whole publicly available literature. 
Our database assimilates large amounts of information from all published articles 
pertaining to specific transcription factors and presents it in a consistent format. Before the data 
is exported to the database, it is first analyzed in-depth and formatted. The goal is to have 
standardized data, taken from credible sources, with comparable parameters. These parameters 
are indexed in such a way that multiple types of searches result in the most relevant results and 
details being displayed. We have also implemented a ranking algorithm that lists the results from 
most relevant to more generic entries corresponding to the search.  
Transcription factors act differently in different environmental conditions. For example, 
their activity varies depending on the species and tissues. Such specific information about 
regulation is often undocumented in database sites. The lack of tissue/cell-type specific 
information is one reason why pathway misregulation in the context of Rb is still not understood. 
Since transcription regulation is highly tissue specific, the classification of transcription family 
members, experimental species, tissues, and cell lines used in experiments can improve 
researchers’ understanding of site-specific cancers.  
In our database, experiment variables are taken into consideration while defining genes. 
For each gene listed, the database provides the user with the source of the publication, 
transcription factor family member, species, tissue/cell line, type of experiment, number of 
experimental replicates, experimental control, quality/fold change, type of regulation, and figure 
number. We have also integrated an “alias match” which would pull up entries listed under a 
gene “alias” when searching for a specific target gene.  
11 
Moreover, there is a need to differentiate between direct and indirect targets due to the 
fact that direct targets can regulate indirect target genes through transcription or other 
mechanisms. Due to the need for such differentiation, the database has an added functionality 
that yields a confident direct target gene list for each specific transcription factor family member 
queried by the user. The classification is based on the confidence score of the gene, which is in 
turn based on score values assigned to the different experiments and other criteria used to 
identify and evaluate target genes, including experimental replicates and the number of available 
papers specific to the gene of interest. The user can query on any of the parameters and even sort 
the results based on gene confidence score, experiment strength, and fold change.  
With such detailed and reliable information, cancer researchers will likely turn their 
attention to this database to seek information on direct targets of their favorite transcription 
factors being studied. Researchers can utilize this database to confirm their own data and make 
educated predictions for future experiments. By making this site publicly available, cancer 
researchers will also be inclined to initiate new research avenues and return information to the 
online site developed here that pertain to their new research findings. 
The basis of cancer is genetics and while this research area is advancing at a rapid pace, 
the mechanisms involved in cancer initiation and progression have lagged behind. This project 
will not only provide insights into the genetic basis of cancer but also lead to the identification of 
potential targets of therapeutic cancer treatments. Identification of the genes involved in 
pathways is a preliminary step in understanding cancer development and proliferation. However, 
such identification will also be of use to all researchers since a complete understanding of the 
pathways and mechanisms within a cell is yet to be attained. Therefore, this database aims to 
supply knowledge that is applicable to all fields of biological research. 
12 
Supporting Data  
 The information in the database necessitates validation. And so, we have compared data 
sets with each other to not only ensure that the data is standardized but to also elucidate any 
similarities or differences between gene-signaling pathways of different transcription factors. 
Currently, all four transcription factors share 43 common target genes. E2f123 and c-Myc share 
336 common targets. Additionally, we have compared multiple microarray data sets including 
one from Rb KO mouse intestinal epithelial cells with the E2f data set and another from 
colorectal cancer (CRC) patients with all transcription factor data sets. Comparison of the 
misregulated genes in the tumor sample with the confident gene targets of all four transcription 
factors showed that a majority of the confident target genes were, in fact, misregulated in the 
colorectal cancer tumors.  
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Materials and Methods 
 
Database content:  
 Specific information was chosen to be listed on the database including: gene name, 
transcription factors family member, PubMed ID, species, tissue/cell line, experiment, control, 
replicates, quality/fold change, regulation, and figure number.  
Experiments chosen for analysis: 
The following assays were chosen and scored to determine and annotate the likelihood of 
a gene being a direct transcriptional target: Nuclear Run-on Assay
18
, Chromatin 
immunoprecipitation coupled with real-time PCR (ChIP-PCR)
19
, ChIP-seq
20
, ChIP-chip
21
, 
ChIP
22
, ChIP-re-ChIP
23
, Electromobility Shift Assay (EMSA)
24
, qPCR
25
, Microarray expression 
platforms (Affymetrix), Reporter Gene Assay
26
, Reverse transcriptase PCR (RT-PCR)
27
, 
Northern Blot
28
, Reverse Northern Blot, RNase Protection Assay (RPA)
29
, ELISA
30
, and 
Western Blot
31
. 
Experiment Scoring:  
 The experiments were divided into two groups: binding and expression. Therefore, they 
were scored separately. By analysis and collaboration with researchers, we have developed a 
scoring matrix for all experiments featured in our database. The confidence score associated with 
each experiment represents the degree of confidence that we associate with a gene if it is labeled 
as a direct target gene by that experiment. Each experiment received a score out of 1 based on its 
methodology and sensitivity to fold change. Binding experiments: ChIP-seq (0.8), ChIP (0.8), 
ChIP-re-ChIP (0.6), EMSA (0.4). Expression experiments: Nuclear Run-on Assay (1), ChIP-
PCR (.8),  ChIP-chip (0.7), Reporter Gene Assay (0.6), qPCR (0.6), Microarray (0.6), RPA (0.5), 
14 
RT-PCR (0.5), Northern Blot (0.5), Reverse Northern Blot (0.5), ELISA (0.4), and Western Blot 
(0.4).  
Analysis of published articles: 
 Published articles pertaining to each transcription factor were obtained mostly through 
PubMed. The experiments presented in the papers were analyzed and the results organized and 
recorded using a spreadsheet. Microarray soft files were obtained from GEO Data Sets and 
analyzed. The information was then exported onto the database. 
Confident potential target gene list: 
 The expression experiments (each entry) were filtered so only those that yielded a fold 
change of |fold change>1.5| were chosen. Each row was assigned a raw score, which is the 
confidence score of the experiment associated with that row. Then an average score of each gene 
in the data set was obtained. The genes were then filtered so that only those that yielded an 
average score value > 0.5 and those that appear more than once in the data set were labeled as 
confident targets genes. By choosing only genes that appear at least twice in a dataset, we are 
ensuring that multiple variables and not just fold change contribute to the confidence of the 
target gene list. 
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Results 
 
 A sample image of the beta prototype database is shown in Figure 1. Currently, we have 
entries for 349 unique published articles for E2fs, 234 for Myc, 160 for Stat proteins, and 84 for 
FoxM1 on the database. Pathway overlap between the target gene lists of all four transcription 
factors has shown that there are 43 common genes (Figure 2A, B). There are 1636 unique gene 
entries for E2fs, 4973 for Myc (c-Myc, N-Myc, and L-Myc), 1951 for FoxM1, and 1272 for Stat 
proteins. Each transcription factor family also has a different number of experiment types based 
on the available publications (Figure 3).  
An ongoing project in the Leone lab will utilize this web-based program to identify 
transcriptional targets of E2F and Myc during intestinal development and cancer. Deletion of 
E2F1-3 or c-Myc in the small intestine can rescue the over-proliferation of intestinal cells in an 
Rb-deficient gut by preventing the misregulation of hundreds of genes. Simultaneous deletion of 
E2F1-3 and c-Myc disrupts the structure in villi by misregulation of gene expression. 
Microarrays have suggested that the transcriptional pathways of both E2F1-3 and c-Myc are 
distinct, but may have significant overlap. The expectation is that E2F and c-Myc will co-bind 
and co-regulate key G2/M cell cycle related target genes such as Ccna2, Cdc20, and Ccnb1 as 
well as G1/S genes including Pcna and Cdc6, explaining how these two transcription factor 
pathways may be regulated by a single tumor suppressor protein (Rb). Overlap between 2945 
E2f123 targets and 7570 c-Myc targets shows 1417 targets which are common to both (Figure 4). 
Many of the 1417 common targets are key cell cycle regulators.  
Supporting E2f data using Rb KO expression data:  
 
Rb is a known direct regulator of E2f in the cell. Previous studies
32
 have shown that when 
Rb is knocked-out, E2f and E2f gene targets are misregulated. Therefore, we performed 
16 
microarray analysis of mouse intestinal epithelial cells with Rb knockout to obtain data sets on 
misregulated E2f target genes. Microarray analysis revealed 701 misregulated genes with a |fold 
change > 1.5| and a p value < 0.05. Comparison of these misregulated genes with the confident 
targets genes of E2f showed that 170 out of 851 targets genes were commonly misregulated. We 
also compared the list of these misregulated genes with the list of confident targets genes of Myc 
and found that 235 out of 2790 targets genes were commonly misregulated.  
Tumor Microarray: 
Microarray analysis of colorectal cancer tissue (CRC) and normal tissue from human 
patients
33
 has yielded 6293 misregulated genes with a |fold change > 1.5| and a p value < 0.05. 
We compared these misregulated genes to the genes in the confident target gene list of the four 
transcription factors. The confident target gene list was initially filtered so only overexpression 
data sets were taken into consideration. Comparison showed that 327 out 841 E2f targets, 1149 
out of 2790 c-Myc targets, and 24 out of 67 FoxM1 targets were commonly misregulated. None 
of the 17 targets of Stat proteins were misregulated in the cancer tissue.  
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Discussion 
 The purpose of our transcription factor database is to elucidate commonly misregulated 
pathways in cancer through the identification of direct transcriptional target genes of 
transcription factors. Our database employs significant criteria such as scoring to define a gene 
as a confident direct target. In addition to this, our database is the first of its kind to use all of the 
publicly available information pertaining to specific transcription factors, analyze the 
information, and present it in a user friendly format. Based on the current mass of data it is 
difficult to determine pathway overlap between all four transcription factors simultaneously. 
However, certain transcription factors such as E2f123 and c-Myc do share many direct targets, 
suggesting possible coregulation of genes and similar signaling pathways within the cell. With 
the future influx of data including large data sets such as microarrays, the pathway overlap 
between E2fs and c-Myc will likely become clearer.  
 To gain a better understanding of the signaling pathways of both E2fs and c-Myc under 
the context of Rb, we compared their confident target genes with misregulated genes in an Rb 
knockout environment. Comparison has shown that only a portion of the E2fs and c-Myc targets 
are misregulated in the Rb knockout environment. The overlap supports a portion of confident 
targets genes on the database. On the other hand, the lack of overlap could tell us something 
about specificity of gene signaling in such an environment. While the complete signaling 
pathways between Rb, E2fs, and c-Myc are still unclear, the valid trends presented in that 
database can be used to support and characterize the relationship between the tumor suppressor 
and both transcription factors.  
 Because E2fs, c-Myc, FoxM1, and Stat are known to be upregulated in most cancers, we 
compared the confident target gene list only from overexpression data to the list of misregulated 
18 
genes in the tumor sample. As expected, we found that many of the confident direct targets of 
E2fs, c-Myc, and FoxM1 were misregulated in the tumor samples. However, the 17 confident 
targets of Stat proteins were not misregulated in the CRC tissue samples. The lack of sufficient 
data on Stat proteins could be the primary reason why there is no overlap between genes. 
Another possibility is that Stat proteins and Stat signaling pathways have higher tissue specificity 
than expected. Nevertheless, the comparison partially supports the data presented in the database. 
By supporting the data sets on the database and by continually updating the information, 
researchers can be sure that the information presented is significant and reliable. And so, we 
believe that cancer researchers will likely turn to our database for the latest information of direct 
targets genes. In the future, we hope to study and provide data on many more cancer-specific 
transcription factors in order to better understand the complexities of cancer.  
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Figure Legends 
 
Figure 1: A screenshot of the current beta prototype database website.  
Figure 2: (A) The data presented in this figure takes into account all gene entries regardless of 
experimental variables and confidence score. (B) The 43 gene targets are not confident gene 
targets.  
Figure 3:  The microarray number has been cut off for all transcription factors. Actual values 
are: 4589 (E2f), 12334 (c-Myc), 2404 (Stat), and 3473 (FoxM1).  
Figure 4: Only overexpression data is taken into account. Diagram does not take into 
consideration confident target gene list.  
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Figures 
 
 
Figure 1: Sample image of the beta prototype database website.  
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Figure 2A: Target gene overlap between transcription factors E2fs, Myc, FoxM1, and Stat 
proteins. 
 
 
 
Figure 2B:  43 gene targets common to transcription factors E2fs, Myc, FoxM1, and Stat 
proteins. 
23 
 
Figure 3: Number of different experiment types per transcription factor family.  
 
 
 
 
Figure 4: Target gene overlap between transcription factors E2f1,2,3 and c-Myc.  
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